Enicepatide
GLP-1 + GIP dual agonist (cAMP-biased) · Roche
Top dose
24 mg
Weight loss
-22.7%
at week 48 · efficacy
AE discontinuation
7.0%
Status
phase 2
Pivotal trial #
- Trial
- CT-388-103 (NCT06525935)
- Indication
- obesity (no T2D)
- Duration
- 48 weeks
- ClinicalTrials.gov
- NCT06525935
- Sponsor
- Roche
Notes #
Phase shown reflects the DATA: the -22.7% is from the Phase 2 CT-388 trial (NCT06525935, primary complete Dec 2025). No Phase 3 has started. Renamed from CT-388. -22.7% efficacy estimand at 48 wks; -18.3% placebo-adjusted treatment estimand. ae_disc_pct uses the deck's Disposition value 'discontinued owing to AE' = 7% (24mg), comparable to peers (tirz 6.2%, sema 7.0%); the deck's Safety slide separately shows 'withdrawn from study due to AE' = 0% (24mg) - a different, narrower metric. Phase 3 ENITH-1/2 recruiting.